Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Jeryczynski, G; Thiele, J; Gisslinger, B; Wölfler, A; Schalling, M; Gleiß, A; Burgstaller, S; Buxhofer-Ausch, V; Sliwa, T; Schlögl, E; Geissler, K; Krauth, MT; Nader, A; Vesely, M; Simonitsch-Klupp, I; Müllauer, L; Beham-Schmid, C; Gisslinger, H.
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
Am J Hematol. 2017; 92(9):885-891 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Beham-Schmid Christine
Wölfler Albert

Dimensions Citations:

Plum Analytics:
The 2016 revised WHO criteria for the diagnosis of pre-fibrotic/early primary myelofibrosis (pre-PMF) require at least one of the following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate dehydrogenase and splenomegaly. In this study, we evaluated the relative frequency of these four criteria in a group of 170 pre-PMF patients and compared them to 225 ET cases. More than 91% of pre-PMF cases showed one or more of these features required for diagnosis, by contrast with only 48% of ET patients. According to clinical data the cumulative risk of progression to advanced/overt PMF in pre-PMF was 36.9% after 15 years. After fitting cox regression models to analyze the impact of the minor criteria on overall survival, only leukocytosis remained as a significant predictor of survival in both pre-PMF and ET. Molecular characterization showed differences in survival in pre-PMF but not ET, with CALR being a more favorable mutation than JAK2. The different outcome of pre-PMF versus ET and associated molecular genetic data supports the concept of two different entities, rather than a continuum of the same disease. Although slightly less than 50% of ET patients also show one or more minor clinical criteria, accurate distinction between ET and pre-PMF is possible by following an integrated approach including histomorphological diagnosis and presence of minor clinical criteria. © 2017 Wiley Periodicals, Inc.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Calreticulin - genetics
Disease-Free Survival -
Female -
Follow-Up Studies -
Humans -
Janus Kinase 2 - genetics
Male -
Middle Aged -
Mutation -
Primary Myelofibrosis - diagnosis
Primary Myelofibrosis - genetics
Primary Myelofibrosis - mortality
Primary Myelofibrosis - therapy
Risk Factors -
Survival Rate -
Thrombocythemia, Essential - diagnosis
Thrombocythemia, Essential - genetics
Thrombocythemia, Essential - mortality
Thrombocythemia, Essential - therapy
World Health Organization -

© Meduni Graz Impressum